Advanced Solid Tumor Clinical Trials in Greenville, South Carolina

6 studies are recruiting for advanced solid tumor in Greenville, South Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

   BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Prisma Health, Greenville, South Carolina

   Locations

   21 in total

   Run by

   OncoC4, Inc.

   See if you can join NCT06635785 on ClinicalTrials.gov

2. A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

   The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Prisma Health Cancer Institute, Greenville, South Carolina

   Locations

   30 in total

   Run by

   Coherus Oncology, Inc.

   See if you can join NCT06657144 on ClinicalTrials.gov

3. An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

   The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Prisma Health-Upstate, Greenville, South Carolina

   Locations

   7 in total

   Run by

   FBD Biologics Limited

   See if you can join NCT06487624 on ClinicalTrials.gov

4. A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

   The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Greenville Hospital System University Medical Center (ITOR), Greenville, South Carolina

   Locations

   8 in total

   Run by

   FBD Biologics Limited

   See if you can join NCT05892718 on ClinicalTrials.gov

5. First in Human, Dose Escalation Study of AN4005

   Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the objective to establish the MTD and/or RP2D of AN4005. Except for Dose Level 0 (50 mg), a traditional "3 +…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Prisma Health Institute for Translational Oncology Research, Greenville, South Carolina

   Locations

   7 in total

   Run by

   Adlai Nortye Biopharma Co., Ltd.

   See if you can join NCT04999384 on ClinicalTrials.gov

6. Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

   This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Greenville Hospital System University Medical Center (ITOR), Greenville, South Carolina

   Locations

   8 in total

   Run by

   Impact Therapeutics, Inc.

   See if you can join NCT05269316 on ClinicalTrials.gov